PeptideDB

NS1652

CAS: 1566-81-0 F: C15H11F3N2O3 W: 324.25

NS1652 is a reversible anion conductance inhibitor, blocks chloride channel, with an IC50 of 1.6 μM in human and mouse
Data collection:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity NS1652 is a reversible anion conductance inhibitor, blocks chloride channel, with an IC50 of 1.6 μM in human and mouse red blood cells.
Target IC50: 1.6 μM (chloride channel, human and mouse red blood cell)
Invitro NS1652 potently inhibits the chloride conductance (IC50, 1.6 μM) in human and mouse red blood cells, but only weakly inhibits VRAC (IC50, 125 μM) in HEK293 cells. NS1652 markedly blocks the NO production with an IC50 of 3.1 μM in BV2 cells. NS1652 also down-regulates iNOS expression at 3 μM, and completely abolishes at 10 μM in BV2 cells[1]. NS1652 (0, 1.0, 3.3, 10, and 20 μM) causes increasing hyperpolarization due to inhibition of the chloride conductance in normal erythrocytes. NS1652 lowers the net KCl loss from deoxygenated sickle cells from about 12 mM cells/h to about 4 mM cells/h. NS1652 (20 μM) completely and reversiblely inhibits the red cell Cl-conductance[2].
In Vivo NS1652 (50 mg/kg, i.v.) blocks murine erythrocyte Cl- conductance by >90% in mice[2].
Name NS1652
CAS 1566-81-0
Formula C15H11F3N2O3
Molar Mass 324.25
Appearance Solid
Transport Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Reference [1]. Kjaer K, et al. Chloride channel blockers inhibit iNOS expression and NO production in IFNgamma-stimulated microglial BV2 cells. Brain Res. 2009 Jul 24;1281:15-24. [2]. Bennekou P, et al. Volume control in sickle cells is facilitated by the novel anion conductance inhibitor NS1652. Blood. 2000 Mar 1;95(5):1842-8.